Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 82

1.

In Reply to Zhang.

Parikh RR, Grossbard ML, Harrison LB, Yahalom J.

Int J Radiat Oncol Biol Phys. 2017 Oct 1;99(2):501. doi: 10.1016/j.ijrobp.2017.04.038. No abstract available.

PMID:
28872005
2.

Survival of Asian Females With Advanced Lung Cancer in the Era of Tyrosine Kinase Inhibitor Therapy.

Becker DJ, Wisnivesky JP, Grossbard ML, Chachoua A, Camidge DR, Levy BP.

Clin Lung Cancer. 2017 Jan;18(1):e35-e40. doi: 10.1016/j.cllc.2016.08.008. Epub 2016 Oct 5.

PMID:
28029530
3.

Association of intensity-modulated radiation therapy on overall survival for patients with Hodgkin lymphoma.

Parikh RR, Grossbard ML, Harrison LB, Yahalom J.

Radiother Oncol. 2016 Jan;118(1):52-9. doi: 10.1016/j.radonc.2015.10.022. Epub 2015 Oct 29.

PMID:
26522061
4.

Impact of delays in definitive treatment on overall survival: a National Cancer Database study of patients with Hodgkin lymphoma.

Parikh RR, Grossbard ML, Harrison LB, Yahalom J.

Leuk Lymphoma. 2016 May;57(5):1074-82. doi: 10.3109/10428194.2015.1094696. Epub 2015 Oct 15.

PMID:
26374099
5.

Early-Stage Classic Hodgkin Lymphoma: The Utilization of Radiation Therapy and Its Impact on Overall Survival.

Parikh RR, Grossbard ML, Harrison LB, Yahalom J.

Int J Radiat Oncol Biol Phys. 2015 Nov 1;93(3):684-93. doi: 10.1016/j.ijrobp.2015.06.039. Epub 2015 Jul 6.

PMID:
26279323
6.

Early-stage nodular lymphocyte-predominant Hodgkin lymphoma: the impact of radiotherapy on overall survival.

Parikh RR, Grossbard ML, Harrison LB, Yahalom J.

Leuk Lymphoma. 2016 Feb;57(2):320-327. doi: 10.3109/10428194.2015.1065978. Epub 2015 Oct 2.

7.

Disparities in survival by insurance status in patients with Hodgkin lymphoma.

Parikh RR, Grossbard ML, Green BL, Harrison LB, Yahalom J.

Cancer. 2015 Oct 1;121(19):3515-24. doi: 10.1002/cncr.29518. Epub 2015 Jun 8.

8.

Long-term outcomes and patterns of failure in orbital lymphoma treated with primary radiotherapy.

Parikh RR, Moskowitz BK, Maher E, Della Rocca D, Della Rocca R, Culliney B, Shapira I, Grossbard ML, Harrison LB, Hu K.

Leuk Lymphoma. 2015 May;56(5):1266-70. doi: 10.3109/10428194.2014.979415. Epub 2015 Jan 28.

PMID:
25356924
9.

Nodular lymphocyte predominant hodgkin lymphoma: biology, diagnosis and treatment.

Goel A, Fan W, Patel AA, Devabhaktuni M, Grossbard ML.

Clin Lymphoma Myeloma Leuk. 2014 Aug;14(4):261-70. doi: 10.1016/j.clml.2014.01.006. Epub 2014 Feb 3. Review.

PMID:
24650975
10.

Impact of oncology drug shortages on patient therapy: unplanned treatment changes.

Becker DJ, Talwar S, Levy BP, Thorn M, Roitman J, Blum RH, Harrison LB, Grossbard ML.

J Oncol Pract. 2013 Jul;9(4):e122-8. doi: 10.1200/JOP.2012.000799. Epub 2013 Mar 19.

11.

Hepatosplenic γδ T-cell lymphoma: an overview.

Visnyei K, Grossbard ML, Shapira I.

Clin Lymphoma Myeloma Leuk. 2013 Aug;13(4):360-9. doi: 10.1016/j.clml.2013.03.011. Review.

PMID:
23876844
12.

Phase I study of oxaliplatin in combination with gemcitabine, irinotecan, and 5-fluorouracil/leucovorin (G-FLIE) in patients with metastatic solid tumors including adenocarcinoma of the pancreas.

Olszewski AJ, Grossbard ML, Chung MS, Chalasani SB, Malamud S, Mirzoyev T, Kozuch PS.

J Gastrointest Cancer. 2013 Jun;44(2):182-9. doi: 10.1007/s12029-012-9466-2.

PMID:
23208490
13.

Vitamin D and breast cancer.

Shao T, Klein P, Grossbard ML.

Oncologist. 2012;17(1):36-45. doi: 10.1634/theoncologist.2011-0278. Epub 2012 Jan 10. Review.

14.

Breast cancer in female-to-male transsexuals: two cases with a review of physiology and management.

Shao T, Grossbard ML, Klein P.

Clin Breast Cancer. 2011 Dec;11(6):417-9. doi: 10.1016/j.clbc.2011.06.006. Epub 2011 Aug 10.

15.

A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254.

Furman RR, Grossbard ML, Johnson JL, Pecora AL, Cassileth PA, Jung SH, Peterson BA, Nadler LM, Freedman A, Bayer RL, Bartlett NL, Hurd DD, Cheson BD; Cancer Leukemia Group B; Eastern Cooperative Oncology Group.

Leuk Lymphoma. 2011 Apr;52(4):587-96. doi: 10.3109/10428194.2010.543714. Epub 2011 Jan 28.

16.

Systemic approaches for multifocal bronchioloalveolar carcinoma: is there an appropriate target?

Levy BP, Drilon A, Makarian L, Patel AA, Grossbard ML.

Oncology (Williston Park). 2010 Sep;24(10):888-98, 900. Review.

17.

Primary central nervous system mucosa-associated lymphoid tissue lymphoma: case report and literature review.

Razaq W, Goel A, Amin A, Grossbard ML.

Clin Lymphoma Myeloma. 2009 Jun;9(3):E5-9. doi: 10.3816/CLM.2009.n.052.

PMID:
19525185
18.

Optimal response to 100 microg/kg anti-Rh(D) in two patients who had suboptimal responses to 75 microg/kg anti-Rh(D).

Varma M, Beautyman EJ, Grossbard ML.

Am J Hematol. 2009 Feb;84(2):124. doi: 10.1002/ajh.21322. No abstract available.

19.

Metastatic pancreatic cancer 2008: is the glass less empty?

Nieto J, Grossbard ML, Kozuch P.

Oncologist. 2008 May;13(5):562-76. doi: 10.1634/theoncologist.2007-0181. Review.

20.

131I tositumomab: a viewpoint by Michael L. Grossbard.

Grossbard ML.

BioDrugs. 2000 Sep;14(3):203-4. No abstract available.

PMID:
18034571

Supplemental Content

Loading ...
Support Center